Discovery Laboratories, Inc. (DSCO), a specialty biotechnology company, announced the United States Patent and Trademark Office, or USPTO, has issued a Notice of Allowance for a patent entitled "Capillary System With Fluidic Element." The license to this patent will provide the company with additional exclusivity regarding certain proprietary and technical aspects of its capillary aerosol generator technology, a key component of its AEROSURF program.
AEROSURF is an investigational combination drug-device product being developed to deliver Discovery Labs' KL4 surfactant in aerosolized form to premature infants with respiratory distress syndrome. The company plans to initiate its AEROSURF phase 2 clinical program in the fourth quarter of 2013.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org